Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Watson “Authorized” Generic Tri-Cyclen Will Share Market With Barr

Executive Summary

Watson will launch an "authorized" generic version of Ortho-McNeil'soral contraceptive Ortho Tri-Cyclen when Barr enters the market with its generic under an agreement between Watson and Ortho announced Oct. 28

You may also be interested in...



Barr Seasonale Print DTC Begins In March; TV Ads Debuting In Second Half

Barr will begin promoting its extended-regimen oral contraceptive Seasonale direct to consumers in March with print ads

Barr Seasonale Print DTC Begins In March; TV Ads Debuting In Second Half

Barr will begin promoting its extended-regimen oral contraceptive Seasonale direct to consumers in March with print ads

Barr Has Plan B For Plan B: Pharmacy Access May Help More Than OTC Switch

Barr believes "behind-the-counter" access for the Plan B emergency contraceptive may be a more significant opportunity for the product than over-the-counter access

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel